Navigation Links
LUMINEX CORPORATION TO HOST INVESTOR EVENT AT ASSOCIATION FOR MOLECULAR PATHOLOGY ANNUAL MEETING
Date:10/29/2013

AUSTIN, Texas, Oct. 29, 2013 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will host an investor event in Phoenix, Arizona at the Association for Molecular Pathology Annual Meeting on Wednesday, November 13, 2013 beginning at 5:30 pm Mountain time.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Patrick J. Balthrop, president and chief executive officer, and other members of the executive management team will provide insight into the company's long-term strategic plans, including a live demonstration of the Company's revolutionary sample-to-answer System, Project ARIES.

Advanced registration is required and attendance will be limited to those registered. To register, please contact Matthew Norman, Government and Investor Relations Manager.  Dinner will be served following the event.

The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived for six months on the website using the 'replay' link.

About Luminex Corporation
Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. The Company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP open-architecture, multi-analyte platform and MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies, that deliver cost-effective and rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. The Company is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.

Contacts:

Matthew Norman, 512.219.8020
Government and Investor Relations Manager
mnorman@luminexcorp.com

Harriss Currie, 512.219.8020
Sr. Vice President and CFO
hcurrie@luminexcorp.com


'/>"/>
SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Reports First Quarter 2012 Results
2. Luminex Corporation Announces Agreement to Acquire GenturaDx
3. Luminex Corporation Second Quarter Earnings Release Scheduled for July 30, 2012
4. Luminex Corporation Reports Second Quarter 2012 Results
5. Luminex Corporation and University Hospital of Wales Collaborate During Olympic Games
6. Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)
7. Luminex Corporation Recognized as Best Technology Company in Austin
8. Luminex Corporation Hosts 10th Annual Planet xMAP Symposium in Monaco
9. Luminex Corporation To Present At Upcoming Investment Conferences In September
10. Luminex Corporation Reports Third Quarter 2012 Results
11. Luminex Corporation To Present At Leerink Swann Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Medical Market Analysis 2016 - Forecast to 2022" report ... The report contains up to date financial data derived from ... of major trends with potential impact on the market during ... market segmentation which comprises of sub markets, regional and country ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):